The effect of infusing hypoxanthine or xanthine on hypoxic-ischemic brain injury in rabbits.
Xanthine oxidase (XO), an enzyme that converts hypoxanthine to xanthine and xanthine to uric acid, is thought to contribute to hypoxic-ischemic brain injury by generating oxygen-free radicals during reperfusion. This is based largely on the observation that inhibition of XO reduces brain damage, but the precise mechanism by which the enzyme contributes to cerebral ischemic injury has not been specifically evaluated. We examined the role of XO in generating oxygen-free radicals that cause brain injury, hypothesizing that if XO generated a significant amount of free radicals during hypoxia-ischemia and reperfusion, providing additional substrate at the time of injury should increase brain damage. Anesthetized rabbits were first subjected to 8 min of cerebral hypoxia by breathing 3% oxygen and then to 8 min of ischemia by raising intracranial pressure equal to mean arterial pressure with an artificial CSF. In order to promote oxygen-free radical generation, hypoxanthine (n=9) or xanthine (n=9), XO substrates, or the vehicle (n=8) was infused intravenously beginning 30 min before and continuing until 30 min after the insult. Animals were sacrificed after 4 h of reperfusion. Neither hypoxanthine nor xanthine infusion increased brain damage. However, administration of hypoxanthine significantly improved somatosensory evoked potential recovery and preserved neurofilament 68 kDa protein, a neuronal structural protein. This study does not support free radical generation by XO as a major cause of damage in cerebral hypoxia-ischemia. Infusion of hypoxanthine reduced cerebral injury suggesting that another mechanism may explain why inhibition of XO reduces brain damage.
Mink
Richard
R
Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Department of Pediatrics, Harbor-UCLA Medical Center, USA. rmink@ucla.edu
Johnston
Jill
J
D000704:Analysis of Variance; D000818:Animals; D002540:Cerebral Cortex / Q000201:enzymology* / Q000473:pathology; D020536:Enzyme Activators / Q000378:metabolism; D005073:Evoked Potentials, Somatosensory / Q000502:physiology; D005609:Free Radicals / Q000378:metabolism; D019271:Hypoxanthine / Q000378:metabolism*; D020925:Hypoxia-Ischemia, Brain / Q000188:drug therapy / Q000201:enzymology*; D007262:Infusions, Intravenous; D008297:Male; D016900:Neurofilament Proteins / Q000378:metabolism; D011817:Rabbits; D011897:Random Allocation; D020127:Recovery of Function / Q000502:physiology; D019820:Xanthine / Q000378:metabolism*; D014969:Xanthine Oxidase / Q000187:drug effects / Q000378:metabolism*
D020536:Enzyme Activators; D005609:Free Radicals; D016900:Neurofilament Proteins; C066858:neurofilament protein NF 68; D019820:Xanthine; D019271:Hypoxanthine; D014969:Xanthine Oxidase